I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment
lung cancer
adenocarcinoma
kras
rigosertib
platinum doublet
- 0 views
- 19 Feb, 2024